[Pubmed] Comparing Efficacy and Safety of Various Monoclonal Antibodies in Myasthenia Gravis: A Systematic Review and Ne
Posté : 17 juin 2026 12:00
Brain Behav. 2026 Jun;16(6):e71557. doi: 10.1002/brb3.71557.
ABSTRACT
BACKGROUND: Myasthenia gravis (MG) is an autoimmune disorder that causes muscle weakness due to disrupted neuromuscular transmission. This network meta-analysis compared the safety and effectiveness of monoclonal antibodies used to treat MG.
METHODS: PubMed, Cochrane Central, and ScienceDirect were searched through June 2025. A frequentist network meta-analysis was conducted using the "meta" and "netmeta" packages in RStudio version 4.3.3. Treatment rankings were determined by p-scores.
RESULTS: Eighteen randomized controlled trials (RCTs) were included in this network meta-analysis. Rozanolixzumab (ROZ) 10 mg/kg significantly decreased the MG Activities of Daily Living (MG-ADL) score compared to placebo (MD = -2.33; 95%CI:[-3.60, -1.06]; p = 0.0003) and was ranked best (p-score = 0.77) regarding this outcome. Batoclimab (BAT) 680 mg significantly reduced the Quantitative MG (QMG) score compared to placebo (MD = -5.17; 95%CI:[-6.44, -3.89]; p
Source: https://pubmed.ncbi.nlm.nih.gov/4230470 ... 2&v=2.20.0